Patient deaths reported in Tecentriq, Cotellic combo arm of mCRC trial

Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer following four deaths, including a case of treatment-related cardiogenic

Read the full 281 word article

User Sign In